Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 30% YoY revenue growth and improved net income and gross margin. The company has no debt and substantial cash reserves, indicating financial stability. Positive factors include a new partnership expanding distribution, a conservative yet confident guidance, and a $10 million share buyback plan. Although there are some uncertainties, such as legal issues with the FDA, the overall sentiment is positive, driven by strong financials and strategic growth initiatives.
Key Financial Performance
Revenue (Q4 2025) $33.8 million, growing 16% year-over-year. Growth attributed to strong performance in e-commerce and ingredient sales.
Net Income (Q4 2025) $4.1 million. Reflects disciplined execution and operational efficiency.
Revenue (Full Year 2025) $129.4 million, representing 30% growth year-over-year. Growth driven by e-commerce and strategic partnerships.
Net Income (Full Year 2025) $17.4 million, compared to $8.6 million in 2024. Increase due to improved operational efficiency and revenue growth.
Gross Margin (Full Year 2025) 64.3%, reflecting improvements in operational efficiency.
Selling and Marketing Expense (Full Year 2025) Improved by approximately 220 basis points as a percentage of net sales year-over-year, indicating better cost management.
R&D Investments (Full Year 2025) Increased by $300,000, reflecting strategic investments in clinical evidence and innovation.
General and Administrative Expense (Full Year 2025) Increased by $8.7 million year-over-year, primarily due to higher employee-related expenses, stock-based compensation, and consulting fees.
Adjusted EBITDA (Full Year 2025) $20.4 million, an $11.9 million improvement compared to fiscal year 2024, driven by revenue growth and operational efficiency.
Cash and Debt (End of 2025) $64.8 million in cash and no debt, indicating strong financial stability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Niagen Plus: Secured a patent for NR and derivatives in intravenous and injectable formulations. Niagen Plus is now present in over 1,200 health clinics, with plans to launch at-home injection kits through a telehealth platform in the first half of 2026.
Tru Niagen Beauty: Launched topical products featuring Niagen in late 2025. Discussions are ongoing with large cosmetics companies for ingredient partnerships.
Expansion in Asia Pacific: Strengthened Tru Niagen's brand presence in Hong Kong and expanded into additional Asia Pacific markets through partnerships like Watsons.
Telehealth and Med Spas: Plans to distribute Niagen Plus at-home injection kits via telehealth platforms and expand presence in med spas.
Divestiture of ChromaDex Reference Standards: Sold the non-core business for $6 million to streamline operations and focus on NAD science.
Improved Financial Performance: Achieved $129.4 million in net revenue for 2025, a 30% year-over-year growth, with a net income of $17.4 million and $64.8 million in cash reserves.
Litigation Against FDA: Challenging the FDA's reversal on NMN's dietary supplement status, asserting strong legal grounds.
Acquisition of NR Patents: Acquired patents for multiple NR salt forms and derivatives to consolidate intellectual property and advance NAD science innovation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Increased competition in the NAD space: The company faces growing competition in the NAD space, which could impact its market share and revenue growth.
FDA's reversal on NMN dietary supplement status: The FDA's decision to reverse its determination on NMN dietary supplements has created confusion in the industry and led to litigation, posing regulatory and legal risks.
Litigation risks: The company is involved in litigation challenging the FDA's reversal on NMN, which could result in financial and operational uncertainties.
Dependence on partnerships: The company relies on partnerships, such as with Watsons, for distribution, which could lead to fluctuations in sales and revenue.
General and administrative expense increase: General and administrative expenses have increased significantly, driven by higher employee-related costs, stock-based compensation, and consulting fees, which could pressure profitability.
Supply chain and inventory management: Growing inventory levels to support scaling operations could lead to inefficiencies or financial strain if not managed effectively.
Uncertain outcomes of clinical trials: Some clinical trials, such as the NOPARK Parkinson's study, did not achieve their primary endpoints, which could impact the company's ability to demonstrate product efficacy and secure regulatory approvals.
Regulatory hurdles for new products: The company faces regulatory challenges in launching new products, such as Niagen Plus injection kits, which could delay market entry or increase costs.
Economic uncertainties: Global market and economic conditions could impact the company's financial performance and operational stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For full year 2026, Niagen Bioscience projects a 10% to 15% growth in net sales year-over-year, excluding revenue from the Analytical Reference Standards & Services segment. This growth is expected to be driven by scaling of the e-commerce business, growth from established partnerships, and additional upside from new partnerships and sales channels.
Gross Margin: A slight improvement in gross margin is anticipated for 2026, attributed to improvements in the supply chain and product mix.
Selling and Marketing Expenses: Selling and marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of net sales (27.4% in 2025). This reflects strategic investments in brand awareness and new channel launches while maintaining efficient customer acquisition spending.
Research and Development (R&D) Expenses: R&D expenses are projected to increase in absolute dollars, driven by investments in pharmaceutical development and external research initiatives to advance product development and innovation.
General and Administrative Expenses: General and administrative expenses are expected to increase by approximately $4 million to $5 million year-over-year, primarily due to investments in infrastructure for scalable growth and increased share-based compensation expense.
Niagen Plus Launch: Niagen Bioscience plans to launch Niagen Plus branded at-home injection kits through its telehealth platform in the first half of 2026, with potential partnerships with other telehealth providers later in the year.
Expansion in Beauty and Cosmetics Market: The company plans to expand its presence in the beauty and cosmetics market in 2026, following the successful launch of Tru Niagen Beauty in late 2025. Discussions with large cosmetics companies for Niagen ingredient partnerships are ongoing.
Litigation Against FDA: Niagen Bioscience is pursuing litigation against the FDA's reversal of its determination on NMN as a dietary supplement. The company believes it has a strong case and will provide updates as the case progresses.
Pharmaceutical Development: The company is advancing its NAD precursor portfolio for pharmaceutical applications, particularly for ataxia telangiectasia (AT). The lead development candidate, NB-4168, is being characterized with the objective of regulatory approval. Potential pathways include a spinout transaction or out-licensing partnership.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations for the number of SKUs for IV bags and injections, and the target audience?
A:Initially, there will be one SKU. The target audience includes the biohacker community, people interested in longevity interventions, and those using peptides or GLP-1 agonists. Early adopters will likely be sophisticated users familiar with the process. Over time, the product will evolve to a simpler liquid form and eventually a pen similar to GLP-1 pens.
Q:What is the guidance for the year, and is it conservative?
A:The guidance is conservative, aiming to avoid overhyping the company. It is based on revenue with a high degree of confidence, considering the unpredictability of the B2B segment.
Q:What are the growth drivers for the year, and are there new distribution channels?
A:Growth drivers include organic growth of Niagen and Tru Niagen, increased awareness through studies and podcasts, and new products like beauty supplements. Distribution channels will expand selectively into retail and internationally, particularly in Asia and possibly the EU.
Q:How is the company addressing increased competition in the NMN space?
A:The company emphasizes the superior quality and effectiveness of its products, Niagen and Tru Niagen. It anticipates potential re-reversal of the FDA's decision on NMN and views increased competition as a way to grow the overall market. The company plans a more aggressive awareness campaign by 2026.
Q:What are the next steps in the lawsuit against the FDA regarding NMN products, and its impact on legal expenses?
A:The lawsuit is expected to proceed as a summary judgment case, taking about a year or slightly more. Legal expenses are not anticipated to be significant.
Q:What is the strategy for share repurchases?
A:The company announced a $10 million buyback, with $250,000 used so far. It plans to use the rest under the set guidelines, considering it a good investment at current prices.
Q:Are there plans for clinical exploration of NR in Parkinson's disease?
A:The company is waiting for the final manuscript and discussions with Dr. Tzoulis, who is optimistic about NR as a preventative measure before standard Parkinson's treatments. Collaboration will focus on prevention.
Q:What is the revenue growth phasing and gross margin guidance for 2026?
A:Revenue growth is expected to be more back-loaded compared to previous years. Gross margin improvement will come from supply chain efficiencies and a changing product mix, with strong performance in the 1,000 milligram SKU and e-commerce.
Q:Does the sales and marketing guidance include additional brand marketing?
A:No, additional brand marketing and advertising are not included in the current sales and marketing guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential growth of new products like cosmetics, IV, and injection products, citing uncertainty about market reactions. They also did not provide detailed insights into the anticipated impact of the lawsuit against the FDA on the company's operations or the exact timeline for the aggressive awareness campaign planned for 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Global
Hospital
NAD IV
NAD research
NAD science
NB
NR NAD
NR administration
NR derivative
NR supplementation
Plus
Results
aging
benefit NR
brain
clock
component
factor Biosciences
fatigue
finding
foundation
group
head study
health
intensity interval
metabolic
metabolism
model
mouse
neuroinflammation
reduction
science Bioscience
study Dr
study Journal
superiority
training age
update
weight
NAGE Transcript
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial performance with a 30% YoY revenue growth and improved net income and gross margin. The company has no debt and substantial cash reserves, indicating financial stability. Positive factors include a new partnership expanding distribution, a conservative yet confident guidance, and a $10 million share buyback plan. Although there are some uncertainties, such as legal issues with the FDA, the overall sentiment is positive, driven by strong financials and strategic growth initiatives.
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises
Positive5-7
The earnings call reveals strong financial performance with a 38% YoY revenue increase, improved gross margins, and a significant net income turnaround. The company also raised its revenue growth outlook to 20%-25%. Despite competitive pressures, the launch of NIAGEN IV and plans for market expansion are promising. The Q&A section highlighted strong interest in new products, although some promotional strategies remain unclear. The lack of debt and strong cash position further enhance financial stability. Overall, the positive financial metrics and optimistic guidance outweigh the concerns, suggesting a positive stock price reaction.
NAGE Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
